[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022014922A - Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos de cyp2c8. - Google Patents

Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos de cyp2c8.

Info

Publication number
MX2022014922A
MX2022014922A MX2022014922A MX2022014922A MX2022014922A MX 2022014922 A MX2022014922 A MX 2022014922A MX 2022014922 A MX2022014922 A MX 2022014922A MX 2022014922 A MX2022014922 A MX 2022014922A MX 2022014922 A MX2022014922 A MX 2022014922A
Authority
MX
Mexico
Prior art keywords
relacorilant
cyp2c8
administered
doses
cancer
Prior art date
Application number
MX2022014922A
Other languages
English (en)
Inventor
Hazel Hunt
Joseph Custodio
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2022014922A publication Critical patent/MX2022014922A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El relacorilant es útil en el tratamiento contra el cáncer y el hipercortisolismo. Diversos fármacos útiles para el tratamiento contra el cáncer o el hipercortisolismo son metabolizados por enzimas CYP2C8. En la presente se describen los efectos de la administración concomitante de relacorilant y un sustrato de CYP2C8. El relacorilant inhibió potentemente a CYP2C8 en una prueba in vitro, lo que indica que se espera que la administración conjunta de relacorilant y un sustrato de CYP2C8 aumente la exposición plasmática del sustrato de CYP2C8 más de cinco veces in vivo. Se espera que se requieran reducciones significativas en las dosis de sustrato de CYP2C8 cuando se administra con relacorilant. De manera inesperada, no se observó tal aumento en la exposición plasmática en estudios en humanos. El solicitante describe que relacorilant puede ser coadministrable de forma segura con dosis no modificadas de sustratos de CYP2C8 tales como pioglitazona, rosiglitazona y enzalutamida. Pueden ser coadministrados relacorilant y dosis no modificadas de enzalutamida para el tratamiento contra el cáncer, por ejemplo, cáncer de próstata. Pueden ser coadministrados relacorilant y dosis no modificadas de pioglitazona o rosiglitazona para el tratamiento contra el cáncer o el hipercortisolismo.
MX2022014922A 2020-05-27 2021-05-26 Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos de cyp2c8. MX2022014922A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063030789P 2020-05-27 2020-05-27
PCT/US2021/034325 WO2021242905A1 (en) 2020-05-27 2021-05-26 Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c8 substrates

Publications (1)

Publication Number Publication Date
MX2022014922A true MX2022014922A (es) 2023-01-04

Family

ID=78707252

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014922A MX2022014922A (es) 2020-05-27 2021-05-26 Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos de cyp2c8.

Country Status (10)

Country Link
US (1) US20210369690A1 (es)
EP (1) EP4157275A4 (es)
JP (1) JP7536118B2 (es)
KR (1) KR20230017821A (es)
CN (1) CN115666573A (es)
AU (1) AU2021282256A1 (es)
CA (1) CA3178767A1 (es)
IL (1) IL298151A (es)
MX (1) MX2022014922A (es)
WO (1) WO2021242905A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673823B2 (en) * 2002-06-04 2004-01-06 Cedars-Sinai Medical Center Use of peroxisome proliferator activated receptor (PPAR)-γ ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome
JP4880671B2 (ja) * 2005-04-05 2012-02-22 エフ.ホフマン−ラ ロシュ アーゲー 1H−ピラゾール4−カルボキシルアミドその製造方法および11β−ヒドロキシステロイドデヒドロゲナーゼとしてのその使用
US8859774B2 (en) * 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CA2984623C (en) 2015-05-18 2023-05-02 Corcept Therapeutics, Inc. Methods for diagnosing and assessing treatment for cushing's syndrome
WO2017120218A1 (en) * 2016-01-04 2017-07-13 The Regents Of The University Of Colorado, A Body Corporate Treatment of prostate cancer cells with fat oxidation inhibitors and enzalutamide
WO2017151613A1 (en) 2016-03-01 2017-09-08 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US20190134004A1 (en) * 2016-06-16 2019-05-09 The University Of Chicago Methods and compositions for treating breast and prostate cancer
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
RU2019129299A (ru) 2017-03-31 2021-04-30 Корсепт Терапьютикс, Инк. Модуляторы глюкокортикоидного рецептора для лечения рака шейки матки
EP3609872A1 (en) * 2017-04-11 2020-02-19 Oric Pharmaceuticals, Inc. Glucocorticoid receptor modulators
MX2020003845A (es) * 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
UA125365C2 (uk) * 2018-11-09 2022-02-23 Корсепт Терапьютікс Інкорпорейтед Спосіб зменшення розміру видимої пухлини гіпофіза
US11389432B2 (en) * 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
IL298149A (en) * 2020-05-27 2023-01-01 Corcept Therapeutics Inc Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4

Also Published As

Publication number Publication date
KR20230017821A (ko) 2023-02-06
CA3178767A1 (en) 2021-12-02
JP2023533142A (ja) 2023-08-02
WO2021242905A1 (en) 2021-12-02
CN115666573A (zh) 2023-01-31
IL298151A (en) 2023-01-01
US20210369690A1 (en) 2021-12-02
EP4157275A4 (en) 2024-06-05
EP4157275A1 (en) 2023-04-05
AU2021282256A1 (en) 2022-12-15
JP7536118B2 (ja) 2024-08-19

Similar Documents

Publication Publication Date Title
NZ597830A (en) Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
Brahmkshatriya et al. Clinical evaluation of Cissus quadrangularis as osteogenic agent in maxillofacial fracture: A pilot study
EA037152B1 (ru) Способ лечения рака
ZA202212283B (en) Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
CN107530309A (zh) 共晶组合物及其药物用途
DE60030842T2 (de) VERWENDUNG VON ZUSAMMENSETZUNGEN ENTHALTEND CldC ALS STRAHLUNGSSENSIBILISATOREN IN DER BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2022014922A (es) Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos de cyp2c8.
WO2011031890A4 (en) Cancer stem cell-targeted and drug resistant cancer therapy
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
WO2019028246A3 (en) METHODS OF TREATING GENETIC HEARING LOSS
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
MX367580B (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer.
IL182462A0 (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
MX2022014923A (es) Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos cyp2c9.
CN104398517A (zh) 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
WO2022270760A8 (ko) 커큐민 유도체와 TGF-β 수용체 억제제의 병용투여를 통한 비알코올성 지방간염 치료 방법
EP1778209B8 (en) Methods and compositions for oral delivery of fts
CN116726022A (zh) 一种egfr抑制剂在制备治疗癌症药物中的用途
CN110151748A (zh) 一种用于治疗前列腺癌的药物组合物
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
Park et al. Anti-Inflammatory Activity of No-Ozone Cold Plasma in Porphyromonas gingivalis Lipopolysaccharide-Induced Periodontitis Rats
WO2024137991A3 (en) Engineered guide rnas and polynucleotides
WO2008068770A2 (en) Pharmaceutical composition containing bicalutamide and a method for its use